Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_3
2
33%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (40.0%)
Phase 42 (40.0%)
N/A1 (20.0%)

Trials by Status

completed583%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completednot_applicable

Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

NCT01196819
unknownphase_3

Cordimax China Post Market Surveillance

NCT03185221
completedphase_4

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

NCT00997763
completedphase_3

Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period

NCT00882219
completedphase_4

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)

NCT01078038
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01196819Not Applicable

Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

Completed
NCT03185221Phase 3

Cordimax China Post Market Surveillance

Unknown
NCT00997763Phase 4

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

Completed
NCT00882219Phase 3

Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period

Completed
NCT01078038Phase 4

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)

Completed
NCT00987506

Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France

Completed

All 6 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
6